There is a need for fast and sensitive methods to evaluate the response of patients with
chronic myeloid leukaemia (CML) to interferon‐α (IFN‐α) therapy to complement cytogenetic …

We analysed 459 samples from 206 chronic myeloid leukaemia (CML) patients at diagnosis
and during or after treatment with interferon‐α (IFN‐α) by quantitative Southern blot analysis …

Abstract Interferon-alpha (IFN-alpha) can be considered as treatment of choice for patients
with chronic myeloid leukaemia (CML) in chronic phase. With this treatment major …

Interferon α (IFN-α) induces cytogenetic responses of variable degree in patients with CML.
We sought to establish the relationship between BCR-ABL transcript numbers measured by …

Interferon-alpha (IFN-alpha) induces cytogenetic responses of variable degree in patients
with chronic myelogenous leukemia (CML). We sought to establish the relationship between …

We used two-color fluorescence in situ hybridization (FISH) to detect BCR/ABL fusion in
interphase nuclei in bone marrow of 17 patients with chronic myeloid leukemia (CML) before …

Cytogenetic analysis is considered pivotal for assessing the remission rate in CML patients
on IFN therapy. On the basis of general agreement, at least 25 metaphases should be …

To determine the source of residual disease detected in patients with chronic myeloid
leukaemia (CML) in complete cytogenetic remission (n= 8) after treatment with interferon‐α …

Interferon-alpha (IFN-alpha) has become a widely used treatment modality in chronic
myelogenous leukemia (CML) and was shown to induce complete hematologic responses …

For patients with chronic myeloid leukaemia, methods for monitoring response to treatment
have changed considerably in recent years. In the 1980s, the principal approach was …